Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. The DRTS news feed highlights the company’s clinical progress, regulatory interactions, manufacturing milestones, and financial updates related to this technology.
Recent news has focused on Alpha Tau’s expanding clinical program. The company has reported final results from a first-in-human pancreatic ductal adenocarcinoma study in Montreal, including disease control and response rates, and is running the IMPACT multi-center pilot trial in the United States combining Alpha DaRT with chemotherapy in newly diagnosed unresectable or metastatic pancreatic cancer. News items also cover pilot studies in recurrent glioblastoma multiforme, including the first reported Alpha DaRT treatment in the brain, as well as FDA-approved trials in locally recurrent prostate cancer.
Regulatory and pre-market developments are another frequent theme. Alpha Tau has announced submission of the first module of its pre-market approval application to the U.S. FDA for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, under a modular PMA framework. The company also reports on Breakthrough Device Designations, participation in the FDA’s Total Product Life Cycle Advisory Program, and marketing authorization processes in other regions.
Operational and corporate updates appear regularly, including receipt of a radioactive material license for the company’s manufacturing facility in New Hampshire, participation in major healthcare and investor conferences, and periodic financial results with corporate commentary. Investors and observers can use the DRTS news page to follow key milestones in Alpha Tau’s efforts to advance Alpha DaRT through clinical development, regulatory review, and preparation for potential commercialization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alpha Tau Medical Ltd. has initiated a feasibility and safety study of its Alpha DaRT cancer therapy, treating the first patient with advanced inoperable pancreatic cancer. Conducted at Jewish General Hospital in Montreal, the study aims to recruit 30 participants with Stage II to IV pancreatic cancer. It will assess the procedure's safety and feasibility, targeting the overall response and survival rates. CEO Uzi Sofer highlighted the trial as a significant milestone in expanding Alpha DaRT's applications. The technology uses alpha radiation for targeted tumor treatment while minimizing damage to surrounding healthy tissues.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced its CFO, Raphi Levy, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 3:30-4:00 PM ET in New York City. This summit focuses on innovations in the radiopharmaceutical sector. Levy will also conduct one-on-one investor meetings during the event. Founded in 2016, Alpha Tau specializes in the development of the Alpha DaRT™, a novel alpha-radiation therapy aimed at treating solid tumors. The technology was initially developed by experts from Tel Aviv University.